XORTX Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3710 33rd St NW, Calgary, Alberta, T2L 2...Phone Number
(403) 455-7727Website
www.xortx.comRevenue
<$5 MillionStock Symbol
XRTXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About XORTX Therapeutics
XORTX Therapeutics is XORTX Therapeutics, a late stage clinical pharmaceutical company dedicated to developing innovative therapies to improve the quality of life of patients with progressive kidney disease. XORTX Therapeutics's programs are designed to manage aberrant purine metabolism and reduce high uric acid and slow progression of kidney disease.Explore more
XORTX Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is XORTX Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if XORTX Therapeutics is spiking on competitors!
XORTX Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if XORTX Therapeutics had a recent Job posting/layoffs
Check if XORTX Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at XORTX Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once XORTX Therapeutics has new funding data
Product Launch: Get notified when XORTX Therapeutics launches new products
Earning: See what the market has to say on XORTX Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to XORTX Therapeutics
Compare insights from companies similar to XORTX Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
XORTX Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
XORTX Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about XORTX Therapeutics.
XORTX Therapeutics financials insights
Gather financial insights about XORTX Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Share Placement
$2.5M
XORTX Therapeutics Tech Stack
A closer look at the technologies used by XORTX Therapeutics
See more technologies
Most Recent Scoops
Promotion
Executive Move
Executive Moves, Promotion
Project
XORTX Therapeutics has announced that it is open to partnership deals, both global and jurisdictional.
Business Development
Project
XORTX Therapeutics is preparing to file a New Drug Application (NDA) for its oxypurinol formulation for the treatment of gout. The company is focused on developing therapies for gout and progressive kidney disease, including a rare kidney disease called polycystic kidney disease.
Product Development, Research & Development, Pharmaceuticals
Product Launch
XORTX Therapeutics has announced its commercialization strategy, which includes preparing for U.S. launch, plans to expand to other jurisdictions with need for allopurinol alternatives, and establishing distribution, manufacturing, and selling group contracts within the next year.
Business Development, Pharmaceuticals
Project
Pharmaceuticals, Pricing
XORTX Therapeutics News & Media
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of iXORTX Announces Closing of US$5 Million Public Offering
CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares ("Common Shares") or common shares equivalents in lieu thereof (“Pre-Funded Warrants”) at a purchase price of US$1.88 (tE.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the exclusive placement agent in connection with a $5 million public offering for XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressiveXORTX Announces US$5 Million Public Offering
CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the pricing of a public offering of 2,659,574 common shares (“Common Shares”) or common shares equivalents in lieu thereof (“Pre-Funded Warrants”) at an offering price of US$1.88 for gross proceeds of US$5 mi
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding XORTX Therapeutics
Sign Up For FreeTo access detailed company insights
XORTX Therapeutics is XORTX Therapeutics, a late stage clinical pharmaceutical company dedicated to developing innovative therapies to improve the quality of life of patients with progressive kidney disease. XORTX Therapeutics's programs are designed to manage aberrant purine metabolism and reduce high uric acid and slow progression of kidney disea... Read More
